United Statesjp.mitsuichemicals.com/en
321Catalyst LP is a U.S.-based corporate venture capital fund launched in May 2025 by Mitsui Chemicals, Inc., a major Japanese chemical manufacturer. With a committed capital of $60 million and a 10-year term, the fund focuses on seed-stage and subsequent investments in innovative startups worldwide.
The fund targets a broad range of industries, including Life & Healthcare, Mobility, ICT, Sustainability, and emerging sectors. Its primary objective is to foster global innovation partnerships and accelerate the development of new products and businesses aligned with Mitsui Chemicals' Long-Term Business Plan VISION 2030, which emphasizes solutions-based business models.
Structurally, 321Catalyst LP is managed by its general partner, 321Catalyst Ventures, Inc., a wholly owned subsidiary of Mitsui Chemicals America, Inc. The limited partner is 321Indigo Ventures, Inc., another 100% subsidiary of Mitsui Chemicals. The fund is headquartered in San Jose, California.
As Mitsui Chemicals' second independent CVC fund—following the 2022 launch of 321FORCE™—it strengthens the company's position in open innovation within the chemical and materials industry. It supports portfolio transformation through strategic equity investments and collaborations, including in biotechnology and sustainability-focused startups.
Operating globally, the fund positions Mitsui Chemicals as an active player in corporate venturing, bridging traditional chemical manufacturing with cutting-edge technologies in biotech, mobility, and digital solutions.
Also known as 321Catalyst™.
None yet. When a new project in the record names 321Catalyst as owner, partner or investor, it shows here.
Links Mitsui's materials and InnoCell plates with an AI-driven closed-loop platform to improve uniformity and manufacture of human cells and organoids for drug discovery and regenerative medicine.
